Armata’s goal is to demonstrate the safety, tolerability and definitive efficacy of multiple therapeutic phage candidates in randomized controlled clinical trials required for regulatory approval and to support commercialization in both acute and chronic indications of high unmet medical need. Armata’s phage cocktails target key antibiotic-resistant and difficult-to-treat pathogens on the World Health Organization’s global priority pathogens list, including Pseudomonas aeruginosa and Staphylococcus aureus. Armata’s fully integrated product development capabilities enable the discovery of optimal phage product candidates, and include the effective adaptation of phages to engineered host cells, essential for efficient process development and resulting in improved purity, stability, and manufacturability, to power rigorous clinical trials. Microbiological surveillance and synthetic biology capabilities drive long-term product life cycle management. To date, Armata has completed three critical Phase 2 trials utilizing two distinct phage cocktails against two different pathogens with the potential to treat chronic pulmonary disease complicated by bacterial infection, as well as acute systemic bacterial infections. In January 2026, we announced the conclusion of an End-of-Phase 2 written response from the U.S. FDA and plans to advance our intravenously-administered S. aureus bacteriophage product candidate, AP-SA02, into a Phase 3 clinical study in complicated S. aureus bacteremia. The Phase 3 study is anticipated to initiate in the second half of 2026.
| Program | Product | Discovery | Preclinical | IND-Cleared | Phase 2 | Partner |
|---|---|---|---|---|---|---|
| Pseudomonas aeruginosa Respiratory Infections | ||||||
| AP-PA02 | CF  |  | ||||
| AP-PA02 | NCFB  | Unpartnered | ||||
| AP-PA03 | Pneumonia | Unpartnered | ||||
| Staphylococcus aureus | ||||||
| AP-SA02 | Bacteremia  | US DoD* | ||||
| AP-SA02 | PJI  | Unpartnered | ||||
| Pseudomonas aeruginosa Respiratory Infections |
|||
|---|---|---|---|
| Discovery | Preclinical | IND-Cleared | Phase 2 |
| Target: AP-PA02Partner: | |||
CF |
|||
| Target: AP-PA02Partner: Unpartnered | |||
NCFB |
|||
| Target: AP-PA03Partner: Unpartnered | |||
Pneumonia |
|||
| Staphylococcus aureus | |||
| Discovery | Preclinical | IND-Cleared | Phase 2 |
| Target: AP-SA02Partner: US DoD* | |||
Bacteremia |
|||
| Target: AP-SA02Partner: Unpartnered | |||
PJI | |||
CF: cystic fibrosis; NCFB: non-CF bronchiectasis; PJI: prosthetic joint infection
SWARM-P.a. NCT Number; NCT04596319; Cystic Fibrosis Foundation TrialFinder
diSArm NCT Number: NCT05184764
Tailwind NCT Number: NCT05616221
*Department of Defense (Naval Medical Research Command, US Army Medical Research Acquisition Activity, Defense Health Agency)